Universität zu Köln

2020

Hombach, Andreas A., Geumann, Ulf, Guenther, Christine, Hermann, Felix G. and Abken, Hinrich (2020). IL7-IL12 Engineered Mesenchymal Stem Cells (MSCs) Improve A CAR T Cell Attack Against Colorectal Cancer Cells. Cells, 9 (4). BASEL: MDPI. ISSN 2073-4409

2019

Hombach, Andreas A., Rappl, Gunter and Abken, Hinrich (2019). Blocking CD30 on T Cells by a Dual Specific CAR for CD30 and Colon Cancer Antigens Improves the CAR T Cell Response against CD30(-) Tumors. Mol. Ther., 27 (10). S. 1825 - 1836. CAMBRIDGE: CELL PRESS. ISSN 1525-0024

2018

Golumba-Nagy, Viktoria, Kuehle, Johannes, Hombach, Andreas A. and Abken, Hinrich (2018). CD28-zeta CAR T Cells Resist TGF-beta Repression through IL-2 Signaling, Which Can Be Mimicked by an Engineered IL-7 Autocrine Loop. Mol. Ther., 26 (9). S. 2218 - 2231. CAMBRIDGE: CELL PRESS. ISSN 1525-0024

2017

Hombach, Andreas A. and Abken, Hinrich (2017). Most Do, but Some Do Not: CD4(+)CD25(-) T Cells, but Not CD4(+)CD25(+) Treg Cells, Are Cytolytic When Redirected by a Chimeric Antigen Receptor (CAR). Cancers, 9 (9). BASEL: MDPI. ISSN 2072-6694

Hombach, Andreas A. and Abken, Hinrich (2017). Shared target antigens on cancer cells and tissue stem cells: go or no-go for CAR T cells? Expert Rev. Clin. Immunol., 13 (2). S. 151 - 156. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1744-8409

Martyniszyn, Alexandra, Krahl, Ann-Christin, Andre, Maya C., Hombach, Andreas A. and Abken, Hinrich (2017). CD20-CD19 Bispecific CAR T Cells for the Treatment of B-Cell Malignancies. Hum. Gene Ther., 28 (12). S. 1147 - 1158. NEW ROCHELLE: MARY ANN LIEBERT, INC. ISSN 1557-7422

2016

Faitschuk, Elena, Hombach, Andreas A., Frenzel, Lukas P., Wendtner, Clemens-Martin and Abken, Hinrich (2016). Chimeric antigen receptor T cells targeting Fc mu receptor selectively eliminate CLL cells while sparing healthy B cells. Blood, 128 (13). S. 1711 - 1723. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Hombach, Andreas A., Goergens, Andre, Chmielewski, Markus, Murke, Florian, Kimpel, Janine ORCID: 0000-0002-5210-7905, Giebel, Bernd ORCID: 0000-0003-2446-948X and Abken, Hinrich (2016). Superior Therapeutic Index in Lymphoma Therapy: CD30(+) CD34(+) Hematopoietic Stem Cells Resist a Chimeric Antigen Receptor T-cell Attack. Mol. Ther., 24 (8). S. 1423 - 1435. CAMBRIDGE: CELL PRESS. ISSN 1525-0024

2014

Chmielewski, Markus, Hombach, Andreas A. and Abken, Hinrich (2014). Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. Immunol. Rev., 257 (1). S. 83 - 91. HOBOKEN: WILEY. ISSN 1600-065X

2013

Hombach, Andreas A., Rappl, Gunter and Abken, Hinrich (2013). Arming Cytokine-induced Killer Cells With Chimeric Antigen Receptors: CD28 Outperforms Combined CD28 OX40 Super-stimulation. Mol. Ther., 21 (12). S. 2268 - 2278. CAMBRIDGE: CELL PRESS. ISSN 1525-0024

2012

Chmielewski, Markus, Hahn, Olga, Rappl, Gunter, Nowak, Michael, Schmidt-Wolf, Ingo H., Hombach, Andreas A. and Abken, Hinrich (2012). T Cells That Target Carcinoembryonic Antigen Eradicate Orthotopic Pancreatic Carcinomas Without Inducing Autoimmune Colitis in Mice. Gastroenterology, 143 (4). S. 1095 - 1110. PHILADELPHIA: W B SAUNDERS CO-ELSEVIER INC. ISSN 0016-5085

Jahn, Tobias, Zuther, Martin, Friedrichs, Bjoern, Heuser, Claudia, Guhlke, Stefan, Abken, Hinrich and Hombach, Andreas A. (2012). An IL12-IL2-Antibody Fusion Protein Targeting Hodgkin's Lymphoma Cells Potentiates Activation of NK and T cells for an Anti-Tumor Attack. PLoS One, 7 (9). SAN FRANCISCO: PUBLIC LIBRARY SCIENCE. ISSN 1932-6203

2011

Chmielewski, Markus, Kopecky, Caroline, Hombach, Andreas A. and Abken, Hinrich (2011). IL-12 Release by Engineered T Cells Expressing Chimeric Antigen Receptors Can Effectively Muster an Antigen-Independent Macrophage Response on Tumor Cells That Have Shut Down Tumor Antigen Expression. Cancer Res., 71 (17). S. 5697 - 5707. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 0008-5472

Hombach, Andreas A. and Abken, Hinrich (2011). Costimulation by chimeric antigen receptors revisited: the T cell antitumor response benefits from combined CD28-OX40 signalling. Int. J. Cancer, 129 (12). S. 2935 - 2945. HOBOKEN: WILEY. ISSN 1097-0215